• 
  Benjamin Colson, Philippe Regnault, Vivien Kraus, Irène Buvat, Valentin Calugaru, et al.. Développement d'un modèle radiomique TEP utilisant une moyenne pondérée pour prédire la localisation de la seconde récidive après réirradiation pour un cancer de la tête et du cou. Congrès de la Société Française de Radiothérapie Oncologique (SFRO), 2024, Paris, France. ⟨hal-04629336⟩
• 
  Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Rayan Bensenane, Arnaud Beddok, Fabienne Lesueur, Alain Fourquet, Mathilde Warcoin, et al.. Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia–Telangiectasia Mutated Variant Carriers. Cancers, 2024, 16 (7), pp.1417. ⟨10.3390/cancers16071417⟩. ⟨hal-04535641⟩
• 
  Hélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, Julie Rondeaux, Sophie Krieger, et al.. Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System. Cancer Research, 2020, 80 (17), pp.3593-3605. ⟨10.1158/0008-5472.CAN-20-0895⟩. ⟨hal-03597164⟩
• 
  Elise Dumas, Beatriz Grandal Rejo, Paul Gougis, Sophie Houzard, Judith Abécassis, et al.. Concomitant medication, comorbidity and survival in patients with breast cancer. Nature Communications, 2024, 15 (1), pp.2966. ⟨10.1038/s41467-024-47002-3⟩. ⟨hal-04673415⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  Davide Soldato, Stefan Michiels, Julie Havas, Antonio Di Meglio, Martina Pagliuca, et al.. Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer. Journal of Clinical Oncology, 2024, pp.JCO2301959. ⟨10.1200/jco.23.01959⟩. ⟨inserm-04639986⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Gilles Houvenaeghel, Alexandre De Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, et al.. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer, 2022, 176, pp.58-69. ⟨10.1016/j.ejca.2022.08.027⟩. ⟨hal-04084967⟩
• 
  Paul Gougis, Anne-Sophie Hamy, Floriane Jochum, Kevin Bihan, Marie Carbonnel, et al.. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns. JAMA Network Open, 2024, 7 (4), pp.e245625. ⟨10.1001/jamanetworkopen.2024.5625⟩. ⟨hal-04573116⟩
• 
  Paul Gougis, Floriane Jochum, Baptiste Abbar, Elise Dumas, Kevin Bihan, et al.. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. EClinicalMedicine, 2024, 70, pp.102536. ⟨10.1016/j.eclinm.2024.102536⟩. ⟨hal-04572045⟩
• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
• 
  Thi-Van-Trinh Tran, Carole Rubino, Rodrigue Allodji, Milena Andruccioli, Stéphane Bardet, et al.. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. British Journal of Cancer, 2022, 127 (12), pp.2118-2124. ⟨10.1038/s41416-022-01982-5⟩. ⟨inserm-04438463⟩
• 
  Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, et al.. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. npj Breast Cancer, 2017, 3 (1), pp.4. ⟨10.1038/s41523-017-0005-y⟩. ⟨cea-04501580⟩
• 
  Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩

75

50